ID   PEO14
AC   CVCL_2687
SY   PE014; PEO-14
DR   EFO; EFO_0005446
DR   ArrayExpress; E-MTAB-691
DR   cancercelllines; CVCL_2687
DR   CancerTools; 151675
DR   Cell_Model_Passport; SIDM01419
DR   Cosmic; 1305318
DR   ECACC; 10032311
DR   GEO; GSM313700
DR   GEO; GSM459856
DR   GEO; GSM659402
DR   GEO; GSM2474998
DR   GEO; GSM4973223
DR   GEO; GSM4973229
DR   GEO; GSM4973235
DR   GEO; GSM4973241
DR   GEO; GSM4973253
DR   GEO; GSM4973265
DR   GEO; GSM4973247
DR   GEO; GSM4973259
DR   GEO; GSM4973271
DR   PRIDE; PXD020764
DR   Progenetix; CVCL_2687
DR   Wikidata; Q54947165
DR   Ximbio; 151675
RX   PubMed=3167863;
RX   PubMed=8824553;
RX   PubMed=20581869;
RX   PubMed=22183581;
RX   PubMed=23415752;
RX   PubMed=25230021;
RX   PubMed=25960936;
RX   PubMed=28196595;
RX   PubMed=28273451;
RX   PubMed=30485824;
RX   PubMed=35028612;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: OCCP ovarian cancer cell line panel.
CC   Doubling time: 108 hours (PubMed=3167863).
CC   HLA typing: A*11:01,11:01; B*35:01,35:01; C*04:01,04:01; DQB1*05:01,05:01; DRB1*01:03,01:03 (PubMed=25960936).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277Phe (c.830G>T); ClinVar=VCV000458567; Zygosity=Unspecified (PubMed=25230021; PubMed=28273451).
CC   Omics: Deep proteome analysis.
CC   Omics: Genome sequenced.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): ECACC; PubMed=22183581; PubMed=25230021; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 11
ST   D18S51: 15
ST   D19S433: 14,15
ST   D21S11: 27,30
ST   D2S1338: 19
ST   D3S1358: 16,18
ST   D5S818: 11,12 (ECACC)
ST   D5S818: 12 (PubMed=22183581; PubMed=25230021; PubMed=30485824)
ST   D7S820: 9,10
ST   D8S1179: 13,14
ST   FGA: 20
ST   Penta D: 9,13
ST   Penta E: 10
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 15,16
DI   NCIt; C5228; Ovarian cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2689 ! PEO23
OI   CVCL_2734 ! TO14
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 24
//
RX   PubMed=3167863;
RA   Langdon S.P., Lawrie S.S., Hay F.G., Hawkes M.M., McDonald A.,
RA   Hayward I.P., Schol D.J., Hilgers J., Leonard R.C.F., Smyth J.F.;
RT   "Characterization and properties of nine human ovarian adenocarcinoma
RT   cell lines.";
RL   Cancer Res. 48:6166-6172(1988).
//
RX   PubMed=8824553; DOI=10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#;
RA   Mullen P., Ritchie A., Langdon S.P., Miller W.R.;
RT   "Effect of Matrigel on the tumorigenicity of human breast and ovarian
RT   carcinoma cell lines.";
RL   Int. J. Cancer 67:816-820(1996).
//
RX   PubMed=20581869; DOI=10.1038/onc.2010.245;
RA   Cooke S.L., Ng C.K.Y., Melnyk N., Garcia M.J., Hardcastle T., Temple J.,
RA   Langdon S.P., Huntsman D.G., Brenton J.D.;
RT   "Genomic analysis of genetic heterogeneity and evolution in high-grade
RT   serous ovarian carcinoma.";
RL   Oncogene 29:4905-4913(2010).
//
RX   PubMed=22183581; DOI=10.1002/path.3980;
RA   Ng C.K.Y., Cooke S.L., Howe K.L., Newman S., Xian J., Temple J.,
RA   Batty E.M., Pole J.C.M., Langdon S.P., Edwards P.A.W., Brenton J.D.;
RT   "The role of tandem duplicator phenotype in tumour evolution in
RT   high-grade serous ovarian cancer.";
RL   J. Pathol. 226:703-712(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:E103988-E103988(2014).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=35028612; DOI=10.1016/j.xcrm.2021.100471;
RA   Huang D.-Q., Chowdhury S., Wang H., Savage S.R., Ivey R.G., Kennedy J.J.,
RA   Whiteaker J.R., Lin C.-W., Hou X.-N., Oberg A.L., Larson M.C., Eskandari N.,
RA   Delisi D.A., Gentile S., Huntoon C.J., Voytovich U.J., Shire Z.J.,
RA   Yu Q., Gygi S.P., Hoofnagle A.N., Herbert Z.T., Lorentzen T.D.,
RA   Calinawan A., Karnitz L.M., Weroha S.J., Kaufmann S.H., Zhang B.,
RA   Wang P., Birrer M.J., Paulovich A.G.;
RT   "Multiomic analysis identifies CPT1A as a potential therapeutic target
RT   in platinum-refractory, high-grade serous ovarian cancer.";
RL   Cell Rep. Med. 2:100471.1-100471.32(2021).
//